Efficacy and Safety
A faster improvement in clinical signs has been observed compared to benazepril alone 1,2,3
Improvement of heart failure symptoms: difference between the time to improvement observed in dogs treated with benazepril alone versus dogs treated with CARDALIS™ (significant difference p<0.05).
The BESST Study - a pivotal efficacy study for FDA approval of CARDALIS™5
|569 dogs enrolled in the study|
* Treatment failure = occurrence of cardiac death/euthanasia due to cardiac cause or worsening/occurrence of cardiac signs
- Data on file: Cardalis™. Marketing authorization file, CEVA Santé Animale, 2012.
- Cardalis™. CVMP assessment report. EMA. August 2012. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_Public_assessment_report/veterinary/002524/WC500131472.pdf
- Cardalis™. EPAR product information. June 2013. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/veterinary/002524/WC500131473.pdf.
- Freedom of Information Summary, NADA #141-538 (July 27, 2020), CARDALIS.
- Coffman, M Guillot, E Blondel, T, et al. Clinical efficacy of a benazepril and spironolactone combination in dogs with congestive heart failure due to myxomatous mitral valve disease: The BEnazepril Spironolactone STudy (BESST)J Vet Intern Med 2021 1 15
CARDALIS and the CARDALIS logo trademarks are the property of Ceva Santé Animale S.A.